Cancer cure for 32 cancer types: results from the EUROCARE-5 study
Abstract Background Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods 7.2 million cancer patients (42 population-based cancer registries in 17 European...
Gespeichert in:
| Veröffentlicht in: | International journal of epidemiology 2020-10, Vol.49 (5), p.1517-1525 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1525 |
|---|---|
| container_issue | 5 |
| container_start_page | 1517 |
| container_title | International journal of epidemiology |
| container_volume | 49 |
| creator | Dal Maso, Luigino Panato, Chiara Tavilla, Andrea Guzzinati, Stefano Serraino, Diego Mallone, Sandra Botta, Laura Boussari, Olayidé Capocaccia, Riccardo Colonna, Marc Crocetti, Emanuele Dumas, Agnes Dyba, Tadek Franceschi, Silvia Gatta, Gemma Gigli, Anna Giusti, Francesco Jooste, Valerie Minicozzi, Pamela Neamtiu, Luciana Romain, Gaëlle Zorzi, Manuel De Angelis, Roberta Francisci, Silvia |
| description | Abstract
Background
Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period.
Methods
7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%.
Results
LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and |
| doi_str_mv | 10.1093/ije/dyaa128 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03088676v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ije/dyaa128</oup_id><sourcerecordid>2446991470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-ef6af6c7c520d3d64ffaa60fb6d6bcda7abcfa62f00bdf46e75981ac2009ae503</originalsourceid><addsrcrecordid>eNp9kM1LwzAYh4Mobk5P3iUnUaQuadOk9TbLdMJgMNw5vM0H62jtTFqh_70dnTt6euHHwwPvg9AtJc-UpNG02Jmp7gBomJyhMWWcBRFP4nM0JhEhQSwEHaEr73eEUMZYeolGUZgmLCVijF4z-FLGYdU6g23tcBRiNUxNtzf-BTvj27Lx2Lq6ws3W4Plmvcpm63kQY9-0urtGFxZKb26Od4I2b_PPbBEsV-8f2WwZKBaLJjCWg-VKqDgkOtKcWQvAic255rnSICBXFnhoCcm1ZdyIOE0oqJCQFExMogl6HLxbKOXeFRW4TtZQyMVsKQ9b_26ScMF_aM8-DOze1d-t8Y2sCq9MWcKXqVsvQ8Z4mlImDtqnAVWu9t4Ze3JTIg-BZR9YHgP39N1R3OaV0Sf2r2gP3A9A3e7_Nf0C4-SCtw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446991470</pqid></control><display><type>article</type><title>Cancer cure for 32 cancer types: results from the EUROCARE-5 study</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dal Maso, Luigino ; Panato, Chiara ; Tavilla, Andrea ; Guzzinati, Stefano ; Serraino, Diego ; Mallone, Sandra ; Botta, Laura ; Boussari, Olayidé ; Capocaccia, Riccardo ; Colonna, Marc ; Crocetti, Emanuele ; Dumas, Agnes ; Dyba, Tadek ; Franceschi, Silvia ; Gatta, Gemma ; Gigli, Anna ; Giusti, Francesco ; Jooste, Valerie ; Minicozzi, Pamela ; Neamtiu, Luciana ; Romain, Gaëlle ; Zorzi, Manuel ; De Angelis, Roberta ; Francisci, Silvia</creator><creatorcontrib>Dal Maso, Luigino ; Panato, Chiara ; Tavilla, Andrea ; Guzzinati, Stefano ; Serraino, Diego ; Mallone, Sandra ; Botta, Laura ; Boussari, Olayidé ; Capocaccia, Riccardo ; Colonna, Marc ; Crocetti, Emanuele ; Dumas, Agnes ; Dyba, Tadek ; Franceschi, Silvia ; Gatta, Gemma ; Gigli, Anna ; Giusti, Francesco ; Jooste, Valerie ; Minicozzi, Pamela ; Neamtiu, Luciana ; Romain, Gaëlle ; Zorzi, Manuel ; De Angelis, Roberta ; Francisci, Silvia ; EUROCARE-5 Working Group ; the EUROCARE-5 Working Group</creatorcontrib><description>Abstract
Background
Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period.
Methods
7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%.
Results
LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65–74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years.
Conclusions
Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients’ quality of life.</description><identifier>ISSN: 0300-5771</identifier><identifier>EISSN: 1464-3685</identifier><identifier>DOI: 10.1093/ije/dyaa128</identifier><identifier>PMID: 32984907</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Europe - epidemiology ; Female ; Humanities and Social Sciences ; Humans ; Life Expectancy ; Life Sciences ; Male ; Melanoma ; Middle Aged ; Neoplasms - epidemiology ; Neoplasms - therapy ; Quality of Life ; Registries ; Santé publique et épidémiologie ; Skin Neoplasms ; Sociology ; Survival Rate ; Young Adult</subject><ispartof>International journal of epidemiology, 2020-10, Vol.49 (5), p.1517-1525</ispartof><rights>The Author(s) 2020; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 2020</rights><rights>The Author(s) 2020; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-ef6af6c7c520d3d64ffaa60fb6d6bcda7abcfa62f00bdf46e75981ac2009ae503</citedby><cites>FETCH-LOGICAL-c457t-ef6af6c7c520d3d64ffaa60fb6d6bcda7abcfa62f00bdf46e75981ac2009ae503</cites><orcidid>0000-0001-6163-200X ; 0000-0001-7948-6952 ; 0000-0003-4181-8071</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1583,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32984907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03088676$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Dal Maso, Luigino</creatorcontrib><creatorcontrib>Panato, Chiara</creatorcontrib><creatorcontrib>Tavilla, Andrea</creatorcontrib><creatorcontrib>Guzzinati, Stefano</creatorcontrib><creatorcontrib>Serraino, Diego</creatorcontrib><creatorcontrib>Mallone, Sandra</creatorcontrib><creatorcontrib>Botta, Laura</creatorcontrib><creatorcontrib>Boussari, Olayidé</creatorcontrib><creatorcontrib>Capocaccia, Riccardo</creatorcontrib><creatorcontrib>Colonna, Marc</creatorcontrib><creatorcontrib>Crocetti, Emanuele</creatorcontrib><creatorcontrib>Dumas, Agnes</creatorcontrib><creatorcontrib>Dyba, Tadek</creatorcontrib><creatorcontrib>Franceschi, Silvia</creatorcontrib><creatorcontrib>Gatta, Gemma</creatorcontrib><creatorcontrib>Gigli, Anna</creatorcontrib><creatorcontrib>Giusti, Francesco</creatorcontrib><creatorcontrib>Jooste, Valerie</creatorcontrib><creatorcontrib>Minicozzi, Pamela</creatorcontrib><creatorcontrib>Neamtiu, Luciana</creatorcontrib><creatorcontrib>Romain, Gaëlle</creatorcontrib><creatorcontrib>Zorzi, Manuel</creatorcontrib><creatorcontrib>De Angelis, Roberta</creatorcontrib><creatorcontrib>Francisci, Silvia</creatorcontrib><creatorcontrib>EUROCARE-5 Working Group</creatorcontrib><creatorcontrib>the EUROCARE-5 Working Group</creatorcontrib><title>Cancer cure for 32 cancer types: results from the EUROCARE-5 study</title><title>International journal of epidemiology</title><addtitle>Int J Epidemiol</addtitle><description>Abstract
Background
Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period.
Methods
7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%.
Results
LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65–74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years.
Conclusions
Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients’ quality of life.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Life Expectancy</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Melanoma</subject><subject>Middle Aged</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - therapy</subject><subject>Quality of Life</subject><subject>Registries</subject><subject>Santé publique et épidémiologie</subject><subject>Skin Neoplasms</subject><subject>Sociology</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>0300-5771</issn><issn>1464-3685</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1LwzAYh4Mobk5P3iUnUaQuadOk9TbLdMJgMNw5vM0H62jtTFqh_70dnTt6euHHwwPvg9AtJc-UpNG02Jmp7gBomJyhMWWcBRFP4nM0JhEhQSwEHaEr73eEUMZYeolGUZgmLCVijF4z-FLGYdU6g23tcBRiNUxNtzf-BTvj27Lx2Lq6ws3W4Plmvcpm63kQY9-0urtGFxZKb26Od4I2b_PPbBEsV-8f2WwZKBaLJjCWg-VKqDgkOtKcWQvAic255rnSICBXFnhoCcm1ZdyIOE0oqJCQFExMogl6HLxbKOXeFRW4TtZQyMVsKQ9b_26ScMF_aM8-DOze1d-t8Y2sCq9MWcKXqVsvQ8Z4mlImDtqnAVWu9t4Ze3JTIg-BZR9YHgP39N1R3OaV0Sf2r2gP3A9A3e7_Nf0C4-SCtw</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Dal Maso, Luigino</creator><creator>Panato, Chiara</creator><creator>Tavilla, Andrea</creator><creator>Guzzinati, Stefano</creator><creator>Serraino, Diego</creator><creator>Mallone, Sandra</creator><creator>Botta, Laura</creator><creator>Boussari, Olayidé</creator><creator>Capocaccia, Riccardo</creator><creator>Colonna, Marc</creator><creator>Crocetti, Emanuele</creator><creator>Dumas, Agnes</creator><creator>Dyba, Tadek</creator><creator>Franceschi, Silvia</creator><creator>Gatta, Gemma</creator><creator>Gigli, Anna</creator><creator>Giusti, Francesco</creator><creator>Jooste, Valerie</creator><creator>Minicozzi, Pamela</creator><creator>Neamtiu, Luciana</creator><creator>Romain, Gaëlle</creator><creator>Zorzi, Manuel</creator><creator>De Angelis, Roberta</creator><creator>Francisci, Silvia</creator><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>BXJBU</scope><orcidid>https://orcid.org/0000-0001-6163-200X</orcidid><orcidid>https://orcid.org/0000-0001-7948-6952</orcidid><orcidid>https://orcid.org/0000-0003-4181-8071</orcidid></search><sort><creationdate>20201001</creationdate><title>Cancer cure for 32 cancer types: results from the EUROCARE-5 study</title><author>Dal Maso, Luigino ; Panato, Chiara ; Tavilla, Andrea ; Guzzinati, Stefano ; Serraino, Diego ; Mallone, Sandra ; Botta, Laura ; Boussari, Olayidé ; Capocaccia, Riccardo ; Colonna, Marc ; Crocetti, Emanuele ; Dumas, Agnes ; Dyba, Tadek ; Franceschi, Silvia ; Gatta, Gemma ; Gigli, Anna ; Giusti, Francesco ; Jooste, Valerie ; Minicozzi, Pamela ; Neamtiu, Luciana ; Romain, Gaëlle ; Zorzi, Manuel ; De Angelis, Roberta ; Francisci, Silvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-ef6af6c7c520d3d64ffaa60fb6d6bcda7abcfa62f00bdf46e75981ac2009ae503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Life Expectancy</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Melanoma</topic><topic>Middle Aged</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - therapy</topic><topic>Quality of Life</topic><topic>Registries</topic><topic>Santé publique et épidémiologie</topic><topic>Skin Neoplasms</topic><topic>Sociology</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dal Maso, Luigino</creatorcontrib><creatorcontrib>Panato, Chiara</creatorcontrib><creatorcontrib>Tavilla, Andrea</creatorcontrib><creatorcontrib>Guzzinati, Stefano</creatorcontrib><creatorcontrib>Serraino, Diego</creatorcontrib><creatorcontrib>Mallone, Sandra</creatorcontrib><creatorcontrib>Botta, Laura</creatorcontrib><creatorcontrib>Boussari, Olayidé</creatorcontrib><creatorcontrib>Capocaccia, Riccardo</creatorcontrib><creatorcontrib>Colonna, Marc</creatorcontrib><creatorcontrib>Crocetti, Emanuele</creatorcontrib><creatorcontrib>Dumas, Agnes</creatorcontrib><creatorcontrib>Dyba, Tadek</creatorcontrib><creatorcontrib>Franceschi, Silvia</creatorcontrib><creatorcontrib>Gatta, Gemma</creatorcontrib><creatorcontrib>Gigli, Anna</creatorcontrib><creatorcontrib>Giusti, Francesco</creatorcontrib><creatorcontrib>Jooste, Valerie</creatorcontrib><creatorcontrib>Minicozzi, Pamela</creatorcontrib><creatorcontrib>Neamtiu, Luciana</creatorcontrib><creatorcontrib>Romain, Gaëlle</creatorcontrib><creatorcontrib>Zorzi, Manuel</creatorcontrib><creatorcontrib>De Angelis, Roberta</creatorcontrib><creatorcontrib>Francisci, Silvia</creatorcontrib><creatorcontrib>EUROCARE-5 Working Group</creatorcontrib><creatorcontrib>the EUROCARE-5 Working Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><jtitle>International journal of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dal Maso, Luigino</au><au>Panato, Chiara</au><au>Tavilla, Andrea</au><au>Guzzinati, Stefano</au><au>Serraino, Diego</au><au>Mallone, Sandra</au><au>Botta, Laura</au><au>Boussari, Olayidé</au><au>Capocaccia, Riccardo</au><au>Colonna, Marc</au><au>Crocetti, Emanuele</au><au>Dumas, Agnes</au><au>Dyba, Tadek</au><au>Franceschi, Silvia</au><au>Gatta, Gemma</au><au>Gigli, Anna</au><au>Giusti, Francesco</au><au>Jooste, Valerie</au><au>Minicozzi, Pamela</au><au>Neamtiu, Luciana</au><au>Romain, Gaëlle</au><au>Zorzi, Manuel</au><au>De Angelis, Roberta</au><au>Francisci, Silvia</au><aucorp>EUROCARE-5 Working Group</aucorp><aucorp>the EUROCARE-5 Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer cure for 32 cancer types: results from the EUROCARE-5 study</atitle><jtitle>International journal of epidemiology</jtitle><addtitle>Int J Epidemiol</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>49</volume><issue>5</issue><spage>1517</spage><epage>1525</epage><pages>1517-1525</pages><issn>0300-5771</issn><eissn>1464-3685</eissn><abstract>Abstract
Background
Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period.
Methods
7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%.
Results
LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65–74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years.
Conclusions
Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients’ quality of life.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>32984907</pmid><doi>10.1093/ije/dyaa128</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6163-200X</orcidid><orcidid>https://orcid.org/0000-0001-7948-6952</orcidid><orcidid>https://orcid.org/0000-0003-4181-8071</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-5771 |
| ispartof | International journal of epidemiology, 2020-10, Vol.49 (5), p.1517-1525 |
| issn | 0300-5771 1464-3685 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03088676v1 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Europe - epidemiology Female Humanities and Social Sciences Humans Life Expectancy Life Sciences Male Melanoma Middle Aged Neoplasms - epidemiology Neoplasms - therapy Quality of Life Registries Santé publique et épidémiologie Skin Neoplasms Sociology Survival Rate Young Adult |
| title | Cancer cure for 32 cancer types: results from the EUROCARE-5 study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A31%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20cure%20for%2032%20cancer%20types:%20results%20from%20the%20EUROCARE-5%20study&rft.jtitle=International%20journal%20of%20epidemiology&rft.au=Dal%20Maso,%20Luigino&rft.aucorp=EUROCARE-5%20Working%20Group&rft.date=2020-10-01&rft.volume=49&rft.issue=5&rft.spage=1517&rft.epage=1525&rft.pages=1517-1525&rft.issn=0300-5771&rft.eissn=1464-3685&rft_id=info:doi/10.1093/ije/dyaa128&rft_dat=%3Cproquest_hal_p%3E2446991470%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446991470&rft_id=info:pmid/32984907&rft_oup_id=10.1093/ije/dyaa128&rfr_iscdi=true |